TITLE

A 3-Month Course of Long-Acting Repeatable Octreotide (Sandostatin LAR) Improves Portal Hypertension in Patients With Cirrhosis: A Randomized Controlled Study

AUTHOR(S)
Spahr, Laurent; Giostra, Emiliano; Frossard, Jean-Louis; Morard, Isabelle; Mentha, Gilles; Hadengue, Antoine
PUB. DATE
July 2007
SOURCE
American Journal of Gastroenterology;Jul2007, Vol. 102 Issue 7, p1397
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: In patients with cirrhosis, acute octreotide administration may transiently decrease the hepatic venous pressure gradient (HVPG). Information on long-term effects of octreotide is limited and controversial. We evaluated portal and systemic hemodynamics following a prolonged administration of long-acting octreotide in patients with cirrhosis. METHODS: Eighteen cirrhotic patients (alcoholic 12; age 55 yr [44–69]; Pugh's score 7.8; HVPG 17.3 mmHg [12–22]), no steatohepatitis on histology, were randomized to intramuscular octreotide 20 mg (group A) q 4 wk for 3 months or placebo (group B) in a double-blind fashion. At baseline and 3 months, we measured the HVPG, systemic hemodynamics, endothelin-1 (ET-1), and vascular endothelial growth factor (VEGF) in hepatic venous blood. RESULTS: Patients remained compensated except for one episode of infection in each group. At 3 months, the HVPG decreased in group A but not in group B (16.5 ± 1.3 to 11.8 ± 1.5 mmHg, P < 0.01; 18.2 ± 1 to 17 ± 1.1 mmHg, P= 0.4). Systemic hemodynamics and liver function remained unchanged. In group A, but not in group B, VEGF decreased (21.2 ± 4.7 to 13.7 ± 3.5 pg/mL, P < 0.01; 22.5 ± 7.8 to 19.2 ± 5.4 pg/mL, P= 0.4). ET-1 remained stable. Changes in HVPG and VEGF were correlated (r = 0.49, P < 0.05). CONCLUSIONS: Three months of long-acting octreotide in selected cirrhotic patients with portal hypertension decreases the HVPG independent of systemic hemodynamics and liver function. The decrease in VEGF blood levels suggests an improvement in splanchnic hyperemia.
ACCESSION #
25489315

 

Related Articles

  • Evaluation of Rectal Mucosal Hemodynamics in Patients with Liver Cirrhosis Using Reflectance Spectrophotometry. Tezuha, Takashi; Akita, Yasushi; Yoshikawa, Nozomi; Mitamura, Keiji // American Journal of Gastroenterology;Jun1997, Vol. 92 Issue 6, p1022 

    Objectives: Portal hypertensive colonopathy is observed in patients with liver cirrhosis. To determine the correlation between rectal mucosal hemodynamics and portal hypertensive colonopathy, we observed rectal mucosal findings and measured rectal mucosal hemodynamics in patients with liver...

  • Regulation of Hepatic Thrombopoietin Production by Portal Hemodynamics in Liver Cirrhosis. Sezai, Shuichi; Kamisaka, Kazuaki; Ikegami, Fumiaki; Usuki, Kensuke; Urabe, Akio; Tahara, Tomoyuki; Kato, Takashi; Miyazaki, Hiroshi // American Journal of Gastroenterology;Jan1998, Vol. 93 Issue 1, p80 

    Objective: This study was designed to clarify how thrombopoietin (TPO) functions in and, to some extent, causes thrombocytopenia complicating liver cirrhosis and portal hypertension. Methods: Our study population consisted of 19 cirrhotic and six noncirrhotic patients who underwent percutaneous...

  • MONITORING OXIDATIVE STRESS ACROSS WORSENING CHILD PUGH CLASS OF CIRRHOSIS. BHANDARI, SUMIT; AGARWAL, MUKUL P.; DWIVEDI, S.; BANERJEE, B. D. // Indian Journal of Medical Sciences;Nov2008, Vol. 62 Issue 11, p444 

    CONTEXT: Oxidative stress has been increasingly implicated in the pathogenesis and progression of cirrhosis. AIMS: We studied oxidative stress in patients with cirrhosis by measuring markers reflecting pro-oxidant (serum malondialdehyde-MDA) and antioxidant factors (RBC catalase-CAT, superoxide...

  • Effect of Transjugular Intrahepatic Portosystemic Shunt Formation on Portal Hypertensive Gastropathy and Gastric Circulation. Mezawa, Shinichi; Homma, Hisato; Ohta, Hidetoshi; Masuko, Eiichi; Doi, Tadashi; Miyanishi, Koji; Takada, Koichi; Kukitsu, Takehiro; Sato, Tsutomu; Niitsu, Yoshiro // American Journal of Gastroenterology;Apr2001, Vol. 96 Issue 4, p1155 

    OBJECTIVES: The aim of this study was to investigate the effect of a transjugular intrahepatic portosystemic shunt (TIPS) on portal hypertensive gastropathy (PHG) and gastric hemodynamics. METHODS: A total of 16 patients with cirrhosis and portal hypertensive gastropathy were prospectively...

  • Chronic Administration of Losartan, an Angiotensin II Receptor Antagonist, is not Effective in Reducing Portal Pressure in Patients with Preascitic Cirrhosis. Tripathi, Dhiraj; Therapondos, George; Lui, Hock F.; Johnston, Neil; Webb, David J.; Hayes, Peter C. // American Journal of Gastroenterology;Feb2004, Vol. 99 Issue 2, p390 

    OBJECTIVES: Plasma angiotensin II (ANG II) concentrations are elevated in cirrhosis and have been implicated as a cause of portal hypertension. We aimed to study both the systemic and portal hemodynamics, and tolerability after chronic administration of losartan, an ANG II receptor...

  • Nicardipine Infusion Improved Hepatic Function But Failed to Reduce Hepatic Venous Pressure Gradient in Patients with Cirrhosis. Iwao, Tadashi; Toyonaga, Atsushi; Ikegami, Motoki; Sugawara, Hiroshi; Sumino, Michihiro; Takagi, Kohsuke; Oho, Kazuhiko; Sakaki, Munenori; Ohkubo, Kazunori; Inoue, Rintaroh; Tanikawa, Kyuichi // American Journal of Gastroenterology;Mar1992, Vol. 87 Issue 3, p326 

    We investigated the effects of nicardipine on systemic and splanchnic hemodynamics and on liver function in 16 patients with cirrhosis and portal hypertension. Patients received a continuous infusion of 0.3 mg/min of nicardipine (n = 10) and a control infusion (n = 6). No significant changes...

  • Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. Klein, Sabine; Herath, Chandana B.; Schierwagen, Robert; Grace, Josephine; Haltenhof, Tom; Uschner, Frank E.; Strassburg, Christian P.; Sauerbruch, Tilman; Walther, Thomas; Angus, Peter W.; Trebicka, Jonel // PLoS ONE;9/25/2015, Vol. 10 Issue 9, p1 

    Background & Aims: Although in cirrhosis with portal hypertension levels of the vasoconstrictor angiotensin II are increased, this is accompanied by increased production of angiotensin (Ang)-(1–7), the endogenous ligand of the Mas receptor (MasR), which blunts hepatic fibrosis and...

  • COMPARISON OF TERLIPRESSIN AND OCTREOTIDE IN INITIAL MANAGEMENT OF ACUTE VARICEAL BLEEDING. ANSARI, IMDAD ALI; AZIZULLAH JALBANI; SHAH, AFTAB HUSSAIN; GURBAKHSHANI, KOURO MAL; SOLANGI, GHULAM AKBAR; HAIKH, ABRAR // Medical Channel;Jul2010, Vol. 16 Issue 3, p385 

    Most patients due to cirrhosis develop esophageal varices due to portal hypertension and present with acute and often fatal gastrointestinal (G.I) bleeding. The purpose of this study was to establish Octreotide or Terlipressin, as the first line of pharmacological therapies in controlling acute...

  • Management Challenges of Liver Cirrhosis. Sadovsky, Richard // American Family Physician;2/15/2000, Vol. 61 Issue 4, p1127 

    Provides information on the study `Cirrhosis of Liver,' by B.S. Anand published in the August 1999 issue of the `Western Journal of Medicine.'

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics